Crinecerfont in a First Clinical Application of a CRH Antagonist: Further Potential Uses Are Still an Open Chapter!
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgad513 ↗Kurz gefasst
Editorial in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von George P Chrousos. Beteiligte Einrichtung: University Research Institute of Maternal and Child Health and Precision Medicine and UNESCO Chair on Adolescent Health Care, National and Kapodistri…. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital, Amines, Thiazoles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
More than 30 years ago, in discussions with the late Wylie Vale and other colleagues, we raised the potential usefulness of an oral, micromolecular corticotropin-releasing hormone or factor (CRH or CRF) antagonist in a long series of disorders characterized by increased CRH secretion, with one of them being classic congenital adrenal hyperplasia (CAH). A table with the potential clinical uses of a CRH antagonist was constructed then, first published in 2002 and updated in 2006 (1, 2). These included mostly stress-related disorders characterized by increased CRH secretion, such as chronic anxiety disorder, melancholic depression, idiopathic insomnia, narcotic withdrawal, premature labor, etc. It is worth describing briefly the CRH and CRH-related peptides and their tissue receptors, going over the predicted potential utility of nonpeptidic CRH antagonists, and discussing the studies by Auchus et al and Newfield et al on the use of “crinecerfont” as an adjunct therapy respectively in adults and adolescents with classic CAH (3, 4). Importantly, crinecerfont is the first micromolecular CRH antagonist to be used successfully in the clinic in the therapy of a major human genetic disorder, the classic form of CAH (3, 4). Classic CAH affects about 30 000 people in the United States and double this number in Europe (5).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Research Institute of Maternal and Child Health and Precision Medicine and UNESCO Chair on Adolescent Health Care, National and Kapodistrian University of Athens, Athens 11527, Greece.
ORCID-Profile: George P Chrousos
Zitieren
APA
Chrousos, G. P. (2024). Crinecerfont in a First Clinical Application of a CRH Antagonist: Further Potential Uses Are Still an Open Chapter!. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad513
Vancouver
Chrousos GP. Crinecerfont in a First Clinical Application of a CRH Antagonist: Further Potential Uses Are Still an Open Chapter!. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad513
BibTeX
@article{Chrousos2024,
author = {Chrousos, George P},
title = {Crinecerfont in a First Clinical Application of a CRH Antagonist: Further Potential Uses Are Still an Open Chapter!},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgad513}
}
EUVIMED